HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Open Access
Publisher Website
Google Scholar
Abstract
The oncoprotein encoded by the HER‐2 oncogene is a member of the HER family of receptor tyrosine kinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER‐2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor‐specific therapy. In addition, HER‐2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell‐mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER‐2 in breast cancer.

This publication has 63 references indexed in Scilit: